United TherapeuticsFRA:UTH -2.65%82 FCF Margin % is 46.39% as of Mar. 2026, which is 39% above its 10-year median of 33.41. GuruFocus rates FRA:UTH with a GF Score™ of 82/100 and a GF Value™ of €345.73 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 958 Drug Manufacturers companies, United Therapeutics ranks better than 96.45% on this metric.
The historical rank and industry rank for United Therapeutics's FCF Margin % or its related term are showing as below:
FRA:UTH'
s FCF Margin % Range Over the Past 10 Years
Min: -20.04 Med: 33.41 Max: 46.95
Current: 31.89
During the past 13 years, the highest FCF Margin % of United Therapeutics was 46.95%. The lowest was -20.04%. And the median was 33.41%.
FRA:UTH's FCF Margin % is ranked better than 96.45% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs FRA:UTH: 31.89
United Therapeutics FCF Margin % Related Terms
United Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for United Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:UTH vs VTRS, NBIX, ZTS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where United Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
United Therapeutics (FRA:UTH) has a FCF Margin % of 46.39% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on United Therapeutics and its competitors. This is 39% above median its historical median of 33.41. According to the industry distribution chart, United Therapeutics ranks #34 out of 958 companies in the Drug Manufacturers industry, placing it in the top 3.5%.
Is United Therapeutics' FCF Margin % too high?
United Therapeutics' current FCF Margin % of 46.39% is 39% above median its 10-year median of 33.41. The Drug Manufacturers industry median FCF Margin % is 2.45. United Therapeutics' value of 46.39% is 1797.3% above this industry median. Based on the distribution chart, United Therapeutics ranks #34 out of 958 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, United Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' FCF Margin % compare to VTRS and NBIX?
According to the Drug Manufacturers industry distribution chart, United Therapeutics ranks #34 out of 958 companies for FCF Margin %. This places United Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 2.45. United Therapeutics' value of 46.39% is 1797.3% above this benchmark. While the company's 10-year median is 33.41 vs. the industry median of 2.45, United Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. United Therapeutics's current FCF Margin % of 46.39% is 1797.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on United Therapeutics and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. United Therapeutics's current FCF Margin % is 46.39%, which is 39% above median its own 10-year median of 33.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (FRA:UTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €345.73, compared to a current price of €473.30 — trading 36.9% above its estimated fair value. The current FCF Margin % is 46.39%, which is 39% above median its 10-year median of 33.41 and 1797.3% above the Drug Manufacturers industry median of 2.45. United Therapeutics' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For United Therapeutics (FRA:UTH), the current FCF Margin % is 46.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is United Therapeutics (FRA:UTH) Overvalued in 2026?
Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued.
The current stock price of €473.30 is trading 36.9% above its estimated GF Value™ of €345.73.
GuruFocus considers United Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:UTH:
FCF Margin %: 46.39% (39% above median its 10-year median of 33.41)
GF Value™: €345.73 vs. price of €473.30 (36.9% above fair value)
Industry Position: 1797.3% above the Drug Manufacturers median (#34 of 958)
No single metric tells the full story. See the FRA:UTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
82GF Score
Get the complete analysis for FRA:UTH
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UTH has been successfully added to your 
